Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation
| العنوان: | Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation |
|---|---|
| المؤلفون: | Kimimori Kamijo, Yoshimitsu Shimomura, Akihito Shinohara, Shohei Mizuno, Minoru Kanaya, Yoshiaki Usui, Sung-Won Kim, Takahide Ara, Ishikazu Mizuno, Takuro Kuriyama, Hideyuki Nakazawa, Ken-ichi Matsuoka, Shigeru Kusumoto, Nobuo Maseki, Masaki Yamaguchi, Takashi Ashida, Makoto Onizuka, Takahiro Fukuda, Yoshiko Atsuta, Eisei Kondo |
| المصدر: | Annals of Hematology. 102:651-661 |
| بيانات النشر: | Springer Science and Business Media LLC, 2023. |
| سنة النشر: | 2023 |
| مصطلحات موضوعية: | Hematology, General Medicine |
| الوصف: | Allogeneic hematopoietic cell transplantation (HCT) offers a possible cure for patients with relapsed and refractory non-Hodgkin lymphoma (NHL) through potentially beneficial graft versus lymphoma effects. However, allogeneic HCT is associated with high nonrelapse mortality (NRM). Fludarabine with reduced-intensity busulfan (Flu/Bu2) and myeloablative busulfan (Flu/Bu4) are commonly used in conditioning regimens for allogeneic HCT; however, data on their use in patients with NHL is limited. We investigated the effect of busulfan dose on outcomes by comparing Flu/Bu2 and Flu/Bu4 in patients with NHL who underwent allogeneic HCT. Our study included 415 adult patients with NHL who received Flu/Bu2 (315 patients) or Flu/Bu4 (100 patients) between January 2008 and December 2019. All patients were enrolled in the Transplant Registry Unified Management Program 2 of the Japanese Data Center for Hematopoietic Cell Transplantation. The primary endpoint was the 5-year overall survival (OS). To minimize potential confounding factors that may influence outcomes, we performed propensity score matching. The 5-year OS was 50.6% (95% confidence interval (CI), 39.4%–60.8%) and 32.2% (95% CI, 22.4–42.4%) in the Flu/Bu2 and Flu/Bu4 groups, respectively (p = 0.006). The hazard ratio comparing the two groups was 2.13 (95% CI, 1.30–3.50; p = 0.003). Both groups had a similar 5-year cumulative incidence of relapse (38.2% vs 41.3%; p = 0.581), and the Flu/Bu4 group had a higher cumulative incidence of 5-year NRM (15.7% vs 31.9%; p = 0.043). In this study, Flu/Bu4 was associated with worse OS compared with Flu/Bu2 because of high NRM in patients with NHL. |
| تدمد: | 1432-0584 0939-5555 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::528424a56fe209c1ad95c4b9e9ea89da https://doi.org/10.1007/s00277-023-05084-x |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi...........528424a56fe209c1ad95c4b9e9ea89da |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 14320584 09395555 |
|---|